Cytek Biosciences (CTKB) Acquisitions (2023 - 2024)

Cytek Biosciences (CTKB) posted Acquisitions of $471000.0 for Q4 2024, up 47000.0% on a QoQ basis from $1000.0 in Q3 2023.

Cytek Biosciences (CTKB) Acquisitions (2023 - 2024) Analysis & Trends

Cytek Biosciences' Acquisitions history runs 2 years deep, the most recent figure standing at $471000.0 for Q4 2024.

Quarterly Acquisitions changed N/A year-over-year to $471000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $471000.0 (down 98.95% YoY) and the FY2024 annual result came in at $471000.0, down 98.95% from the prior year.
Acquisitions was $471000.0 for Q4 2024 at Cytek Biosciences, up from $1000.0 in the prior quarter.
Across five years, Acquisitions topped out at $44.9 million in Q1 2023 and bottomed at $1000.0 in Q3 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Acquisitions (Qtr)
1	Abbott Laboratories	201.40 Bn	194.75 Bn	6.27 Bn	-
2	Stryker	122.29 Bn	119.41 Bn	3.81 Bn	22.00 Mn
3	Medtronic	105.01 Bn	96.40 Bn	6.41 Bn	406.00 Mn
4	Boston Scientific	64.81 Bn	63.59 Bn	3.61 Bn	523.00 Mn
5	Edwards Lifesciences	55.28 Bn	51.60 Bn	1.29 Bn	-
6	Dexcom	29.06 Bn	27.94 Bn	750.30 Mn	-
7	Koninklijke Philips	29.02 Bn	25.93 Bn	2.07 Bn	-268.10 Mn
8	GE HealthCare Technologies	28.27 Bn	26.20 Bn	1.98 Bn	2.30 Bn
9	Smith & Nephew	25.80 Bn	25.22 Bn	-	-
10	Cytek Biosciences	586.89 Mn	521.19 Mn	21.25 Mn	-

Download Data